Sanofi : EC Oks Enjaymo For Treatment Of Hemolytic Anemia In Adult With Cold Agglutinin Disease
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Sanofi – Aventis Groupe said that the European Commission has granted marketing authorization for Enjaymo (sutimlimab) for the treatment of hemolytic anemia in adult patients with cold agglutinin disease, a rare, serious, and chronic autoimmune hemolytic anemia, where
:max_bytes(150000):strip_icc():format(jpeg)/Mediation-56a260535f9b58b7d0c975bb.jpg "How Divorce Impacts Your Credit Score")
:max_bytes(150000):strip_icc():format(jpeg)/bankers-9e9fc2e9cdb8479eb443b9783b436848.jpg "What Is a High-Yield Savings Account?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1556517575-d380026162654742ad89f5a8ef134d40.jpg "The Main Types of Annuities Made Easy")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1500340373-9a9166e04b064f1d926066341a5e27f8.jpg "Next Fed Meeting: When It Is In September and What To Expect")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1371757399-3329dac503a74576a455122fc2b08246.jpg "<div>9 Major Medicare Changes for 2025 and How They'll Impact Your Coverage</div>")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1064987572-1a79077cb179458dbbcecc5ac1b660df.jpg "Average Equity In U.S. Homes: Overview, FAQs")